Myopia Drops

Studies show that a low dose of atropine, typically administered as eye drops in the evening, has the potential to significantly slow the progression of myopia in children – helping prevent severe nearsightedness.1 2

To make caring for children's vision simpler, OSRX offers three low-dose atropine drops. We now compound 0.01%, 0.025% and 0.05% concentrations, allowing you to customize myopia treatment by patient. Our OMNI atropine eye drops ship directly to your patients or practice (your choice) at no added cost.

How to Prescribe:  New prescribers must complete an OSRX account form. Once completed, a member of our staff will contact you to discuss pricing, ordering options and shipping details. 

Questions? Check out our FAQ.

Atropine Sulfate 0.01%
Sterile Ophthalmic Solution 

Potential Contraindications

3.5 mL

Atropine Sulfate 0.025%
Sterile Ophthalmic Solution 

Potential Contraindications

3.5 mL

Atropine Sulfate 0.05%
Sterile Ophthalmic Solution

Potential Contraindications

3.5 mL

Watch our streamlined approach to Rx fulfillment, including how we process, formulate, and ship all patient-specific medications from our PCAB-accredited 503A compounding pharmacy in Missoula, Montana.

 

"I've found the low dose atropine medications from OSRX to be an excellent adjunct to my myopia management arsenal ... my patients are happy with the price and convenience of direct shipments to their homes. I would highly recommend OSRX for all your practice's compounding needs."
- DR. ROBERT GEROWITZ, OD, FIAO

"Since recently launching our low-dose atropine program for myopia control, I've already prescribed OSRX's drops to many of my patients as adjunct therapy with Ortho-K and stand-alone therapy for myopia control. Due to the low concentration, patients rarely experience any side effects typical of atropine in higher concentrations. I truly believe prescribing atropine drops to myopic children has become the standard of care."
- DR. DENNIS LEUNG, OD, GOLDEN VISION OPTOMETRY

1Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2, Chia, Audrey et al., Ophthalmology, Volume 123, Issue 2, 391 – 399

2Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019;126(1):113-124. doi:10.1016/j.ophtha.2018.05.029

Professional Disclosure:  Dr. Leung is on the Medical Advisory Board of Ocular Science® (an affiliate of OSRX) and has a financial interest in the company.

OSRX operates in full compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.